Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Abstract Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hema...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-06-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13045-019-0746-1 |
| _version_ | 1818240039071514624 |
|---|---|
| author | Hao Wang Gurbakhash Kaur Alexander I. Sankin Fuxiang Chen Fangxia Guan Xingxing Zang |
| author_facet | Hao Wang Gurbakhash Kaur Alexander I. Sankin Fuxiang Chen Fangxia Guan Xingxing Zang |
| author_sort | Hao Wang |
| collection | DOAJ |
| description | Abstract Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies. |
| first_indexed | 2024-12-12T13:07:06Z |
| format | Article |
| id | doaj.art-f6ccd84fefa4410fa7796f34e70456ff |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-12-12T13:07:06Z |
| publishDate | 2019-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-f6ccd84fefa4410fa7796f34e70456ff2022-12-22T00:23:38ZengBMCJournal of Hematology & Oncology1756-87222019-06-0112112010.1186/s13045-019-0746-1Immune checkpoint blockade and CAR-T cell therapy in hematologic malignanciesHao Wang0Gurbakhash Kaur1Alexander I. Sankin2Fuxiang Chen3Fangxia Guan4Xingxing Zang5Department of Microbiology and Immunology, Albert Einstein College of MedicineDepartment of Medical Oncology, Montefiore Medical Center, Albert Einstein College of MedicineDepartment of Urology, Montefiore Medical Center, Albert Einstein College of MedicineNinth People’s Hospital, Shanghai Jiao Tong University School of MedicineSchool of Life Sciences, Zhengzhou UniversityDepartment of Microbiology and Immunology, Albert Einstein College of MedicineAbstract Harnessing the power of the immune system to recognize and eliminate cancer cells is a longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune checkpoint blockade (ICB) and chimeric antigen receptor T (CAR-T) cell therapy have proven to be safe and effective in hematologic malignancies. Despite the unprecedented success of ICB and CAR-T therapy, only a subset of patients can benefit partially due to immune dysfunction and lack of appropriate targets. Here, we review the preclinical and clinical advances of CTLA-4 and PD-L1/PD-1-based ICB and CD19-specific CAR-T cell therapy in hematologic malignancies. We also discuss the basic research and ongoing clinical trials on emerging immune checkpoints (Galectin-9/Tim-3, CD70/CD27, LAG-3, and LILRBs) and on new targets for CAR-T cell therapy (CD22, CD33, CD123, BCMA, CD38, and CD138) for the treatment of hematologic malignancies.http://link.springer.com/article/10.1186/s13045-019-0746-1Hematologic malignanciesImmune checkpointsCAR-TImmunotherapyCTLA-4PD-1 |
| spellingShingle | Hao Wang Gurbakhash Kaur Alexander I. Sankin Fuxiang Chen Fangxia Guan Xingxing Zang Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies Journal of Hematology & Oncology Hematologic malignancies Immune checkpoints CAR-T Immunotherapy CTLA-4 PD-1 |
| title | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies |
| title_full | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies |
| title_fullStr | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies |
| title_full_unstemmed | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies |
| title_short | Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies |
| title_sort | immune checkpoint blockade and car t cell therapy in hematologic malignancies |
| topic | Hematologic malignancies Immune checkpoints CAR-T Immunotherapy CTLA-4 PD-1 |
| url | http://link.springer.com/article/10.1186/s13045-019-0746-1 |
| work_keys_str_mv | AT haowang immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies AT gurbakhashkaur immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies AT alexanderisankin immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies AT fuxiangchen immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies AT fangxiaguan immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies AT xingxingzang immunecheckpointblockadeandcartcelltherapyinhematologicmalignancies |